We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
+12.05%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$70.5M
AUM Growth
–
Cap. Flow
+$69.7M
Cap. Flow %
98.82%
Top 10 Hldgs %
77.88%
Holding
45
New
45
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$10.9M
2
BMY icon
Bristol-Myers Squibb
BMY
+$9.65M
3
CELG
Celgene Corp
CELG
+$9.26M
4
MRK icon
Merck
MRK
+$5.5M
5
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$3.98M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 91.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTAE
26
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$375K 0.53%
+20,720
New +$285K
TBRA
27
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$352K 0.5%
+35,000
New +$364K
GWPH
28
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$347K 0.49%
+5,000
New +$407K
RDHL
29
Redhill Biopharma
RDHL
$4.26M
$309K 0.44%
+24
New +$299K
KMDA icon
30
Kamada
KMDA
$410M
$302K 0.43%
+72,000
New +$286K
SRRA
31
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$301K 0.43%
+500
New +$338K
CDMO
32
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
$287K 0.41%
+35,000
New +$283K
MACK
33
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$284K 0.4%
+4,576
New +$322K
SCYX icon
34
SCYNEXIS
SCYX
$37.4M
$246K 0.35%
+496
New +$261K
AAAP
35
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$235K 0.33%
+7,500
New +$208K
NEOS
36
DELISTED
Neos Therapeutics, Inc
NEOS
$215K 0.31%
+15,000
New +$226K
NERV icon
37
Minerva Neurosciences
NERV
$196M
$207K 0.29%
+4,263
New +$178K
MRNS
38
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$191K 0.27%
+6,250
New +$183K
NTBL
39
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$175K 0.25%
+952
New +$201K
CPXX
40
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
$158K 0.22%
+90,000
New +$154K
ZYNE
41
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$151K 0.21%
+15,000
New +$199K
DARE icon
42
Dare Bioscience
DARE
$18M
$140K 0.2%
+417
New +$173K
FCSC
43
DELISTED
Fibrocell Science Inc.
FCSC
$137K 0.19%
+2,000
New +$144K
TLOG
44
DELISTED
TetraLogic Pharmaceuticals Corporation
TLOG
$111K 0.16%
+64,000
New +$113K
GNVC
45
DELISTED
GenVec, Inc.
GNVC
$35K 0.05%
+1,910
New +$36.5K
1
2

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q4 2015 Portfolio in Review

Q4 2015 is the first quarter with a 13F filing on record for Nexthera Capital, which disclosed 45 positions worth $70.5M. Its ten largest holdings account for 78% of the portfolio.

Its largest position is Pfizer: 347,820 shares worth $10.7M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets.

  • Nexthera Capital's largest Q4 2015 buy was Pfizer: 347,820 shares worth $10.7M.
  • Nexthera Capital's ten largest holdings make up 78% of its $70.5M portfolio in Q4 2015.
  • Nexthera Capital disclosed 45 positions in Q4 2015, its first 13F filing on record.

Based on Nexthera Capital's 13F filing for Q4 2015, filed 16 Feb 2016.